

10/25/02

Requester's Full Name: DAVID LUKTON Examiner #: 71263 Date: 10/25/02  
Art Unit: 1053 Phone Number 301 83213 Serial Number: 09/447226  
Mail Box and Bldg/Room Location: Mail Box: 9B01; Exr Rm: 9B05 Results Format Preferred (circle) PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*


Title of Invention: PEPTIDE ANTIANGIOGENIC DRUGS

Applicants: HENKIN, JACK; HAVIV, FORTUNA; BRADLEY, MICHAEL F.; KALVIN, DOUGLAS M.; SCHNEIDER, ANDREW J.

Earliest priority date 5/22/98

\*\*\*\*\*

Applicants are claiming the following peptides:



R1 = acetyl, HOOC-CH<sub>2</sub>-CH<sub>2</sub>-CO-, C<sub>6</sub>H<sub>5</sub>-CO-  
[R1 cannot be hydrogen]

R2 = methyl, -(CH<sub>2</sub>)<sub>n</sub>-COOH, -(CH<sub>2</sub>)<sub>n</sub>-CONH<sub>2</sub>, -CH<sub>2</sub>-CH<sub>2</sub>-SCH<sub>3</sub>,  
-CH<sub>2</sub>-OH, -(CH<sub>2</sub>)<sub>3</sub>-NH-CONH<sub>2</sub>

R3 = alkyl, hydrogen, -CH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>, -(CH<sub>2</sub>)<sub>n</sub>-COOH, -(CH<sub>2</sub>)<sub>n</sub>-CONH<sub>2</sub>,  
-CH<sub>2</sub>-CH<sub>2</sub>-SCH<sub>3</sub>, -CH<sub>2</sub>-OH

\*\*\*\*\*  
STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Shippam</u>	NA Sequence (#) _____	STN _____
Searcher Phone #: _____	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) _____	Questel/Orbit _____
Date Searcher Picked Up: _____	Bibliographic _____	Dr.Link _____
Date Completed: <u>11/29/02</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Clerical Prep Time: _____	Patent Family _____	WWW/Internet _____
Online Time: _____	Other _____	Other (specify) _____

01/4/17, 220

R4 = alkyl, hydrogen,  $-\text{CH}_2-\text{C}_6\text{H}_5$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{CONH}_2$ ,  
 $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{OH}$ ,  $-(\text{CH}_2)_3-\text{NH}-\text{CONH}_2$ ,  $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$   
 $-\text{CH}_2-\text{SH}$

R5 = anything, provided that the carbon bearing R5 is of the D-configuration

R6 = alkyl, hydrogen,  $-\text{CH}_2-\text{C}_6\text{H}_5$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{CONH}_2$ ,  
 $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{OH}$ ,  $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{CH}=\text{CH}_2$ ,  
imidazolymethyl, indolymethyl,  $-\text{CH}_2-\text{SH}$

R7 = alkyl, hydrogen,  $-\text{CH}_2-\text{C}_6\text{H}_5$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{CONH}_2$ ,  
 $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{OH}$ ,  $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{CH}=\text{CH}_2$ ,  
imidazolymethyl, indolymethyl,  $-\text{CH}_2-\text{SH}$

R8 = alkyl, hydrogen,  $-\text{CH}_2-\text{C}_6\text{H}_5$ ,  $-(\text{CH}_2)_n-\text{COOH}$ ,  $-(\text{CH}_2)_n-\text{CONH}_2$ ,  
 $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{OH}$ ,  $-\text{CH}_2-\text{CH}_2-\text{SCH}_3$ ,  $-\text{CH}_2-\text{CH}=\text{CH}_2$ ,  
imidazolymethyl, indolymethyl,  $-\text{CH}_2-\text{SH}$ ,  $-(\text{CH}_2)_3-\text{NH}-\text{CONH}_2$ .

R9:  $-(\text{CH}_2)_3-\text{NHC}(=\text{NH})\text{NH}_2$ , imidazolymethyl,  $-(\text{CH}_2)_3-\text{NH}-\text{CONH}_2$ ,  
 $-(\text{CH}_2)_4-\text{NH}_2$

R10: alkyl,  $-\text{CH}_2-\text{OH}$ ,  $-\text{CH}_2-\text{C}_6\text{H}_5$


R11: anything, but can contain no more than one amino acid.

n = 1 or 2

FILE COVERS 1907 - 26 Oct 2002 VOL 137 ISS 18  
FILE LAST UPDATED: 25 Oct 2002 (20021025/ED)

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

```
=> d stat que 124
L1          STR
```


$$\begin{array}{ccccccccccccccc}
 & & 35 & & & & 36 & & & & & & & & \\
 & & \text{O} & & & & \text{O} & & & & & & & & \\
 & & || & & & & || & & & & & & & & \\
 \sim & \text{C} \sim & \text{C} \sim & \text{N} \sim & \text{C} \sim & \text{C} \sim & \text{N} \sim & \text{C} \sim & \text{C} \equiv & \text{O} \\
 20 & 22 & 23 & 24 & 25 & 26 & 27 & 28 & 37
 \end{array}$$

Page 1

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 50


STEREO ATTRIBUTES: NONE

L11 39893 SEA FILE=REGISTRY SSS FUL L1

L13 STR



Page 1-A



Page 1-B

VAR G1=49/41/AC

VAR G2=59/64/69/57

VAR G3=53/54/55/56/52

REP G4=(2-2) C

REP G5=(3-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED



GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 73

STEREO ATTRIBUTES: NONE

L14 STR



Page 1-A



Page 1-B

VAR G1=49/41/AC

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 58

STEREO ATTRIBUTES: NONE

L17 STR



Page 1-A



Page 1-B

VAR G1=49/41/AC  
 VAR G2=ME/52/60  
 REP G3=(0-1) C  
 VAR G5=COOH/55/57/OH  
 REP G6=(2-2) C  
 VAR G7=ME/ET/I-PR/N-PR/I-BU/N-BU/T-BU/S-BU/75/67  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 75

STEREO ATTRIBUTES: NONE

L18 282 SEA FILE=REGISTRY SUB=L11 SSS FUL (L17 AND L13) NOT L14  
 L19 231 SEA FILE=HCAPLUS ABB=ON PLU=ON L18  
 L22 405 SEA FILE=REGISTRY ABB=ON PLU=ON ANGIOG?  
 L23 17434 SEA FILE=HCAPLUS ABB=ON PLU=ON L22 OR ?ANGIOGEN?  
 L24 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L19 AND L23

=&gt;

=&gt;

=&gt; d ibib abs hitrn l24 1-2

L24 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:123823 HCAPLUS

DOCUMENT NUMBER: 134:192229

TITLE: Mouse monoclonal antibody recognizing human VEGF receptor KDR, its humanization, and its use for treating abnormal neovascularization

INVENTOR(S): Shitara, Kenya; Sato, Hidenao; Nakamura, Kazuyasu; Ueno, Hironao

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 64 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001046066	A2	20010220	JP 1999-220545	19990803

AB The cDNA encoding the neutralizing mouse monoclonal antibodies KM1992 and KM1995 specific to human VEGF receptor KDR are isolated from hybridomas FERM BP-6217 and FERM BP-6218, resp., and their complementarity detg. regions (CDRs) of both H and L chains detd. The CDR1, CDR2, and CDR3 of VH and VL from both KM1992 and KM1995 are used for the construction of humanized antibodies. Plasmids pKANTEX1992 and pKANTEX1995 are used for the transformation of rat myeloma cells YB2/0 for expression. The humanized antibodies thus prepd. are able to recognize KDR, but not Flt-1. Claimed are methods for recombinant prepn. of the antibodies, methods for immunoassay of KDR or detecting the cells expressing KDR, diagnostics or therapeutics contg. the antibodies for the diseases assocd. with abnormal neovascularization such as solid tumors, rheumatoid arthritis, diabetic retinopathy, premature retinopathy, psoriasis, etc.

IT **326622-01-9P**  
 RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (CDR2 of VH of monoclonal antibody KM1995; mouse monoclonal antibody recognizing human VEGF receptor KDR, humanization, and use for treating abnormal neovascularization)

L24 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:335430 HCAPLUS

DOCUMENT NUMBER: 133:802

TITLE: Inhibition of **angiogenesis** and endothelial cell proliferation by high-molecular-weight kininogen and peptide analogs thereof

INVENTOR(S): McCrae, R. Keith

PATENT ASSIGNEE(S): Temple University - of the Commonwealth System of Higher Education, USA

SOURCE: PCT Int. Appl., 52 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027866	A1	20000518	WO 1999-US26419	19991105

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
 SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1137659 A1 20011004 EP 1999-962723 19991105  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2002529474 T2 20020910 JP 2000-581043 19991105  
 PRIORITY APPLN. INFO.: US 1998-107833P P 19981110  
 WO 1999-US26419 W 19991105

OTHER SOURCE(S): MARPAT 133:802

AB Two-chain high-mol.-wt. kininogen, and peptide analogs thereof having  
 homol. to sites within kininogen domain 5, are potent inhibitors of  
**angiogenesis**. The peptides have the formula X1-His-Lys-X-Lys-X2  
 (X = any amino acid; X1, X2= 0-12 amino acids, more preferably 0-6 amino  
 acids, most preferably 0-3 amino acids). X is preferably an amino acid  
 having a nonpolar side chain, or a polar side chain which is uncharged at  
 pH 6.0 to 7.0. X is most preferably Asn, Phe or His. Methods of  
 inhibiting endothelial cell proliferation and **angiogenesis** are  
 provided.

IT **268728-68-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (high-mol.-wt. kininogen and peptide analogs for inhibition of  
**angiogenesis** and endothelial cell proliferation)

IT **268728-65-0**

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL  
 (Biological study)  
 (high-mol.-wt. kininogen and peptide analogs for inhibition of  
**angiogenesis** and endothelial cell proliferation)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>  
 =>

=> select hit rn 124 1-2  
 E1 THROUGH E3 ASSIGNED

=> fil reg  
 FILE 'REGISTRY' ENTERED AT 17:23:55 ON 26 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 25 OCT 2002 HIGHEST RN 466118-13-8  
 DICTIONARY FILE UPDATES: 25 OCT 2002 HIGHEST RN 466118-13-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP



PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>  
=>

=> s e1-e3

1 268728-65-0/BI  
(268728-65-0/RN)

1 268728-68-3/BI  
(268728-68-3/RN)

1 326622-01-9/BI  
(326622-01-9/RN)

L26 3 (268728-65-0/BI OR 268728-68-3/BI OR 326622-01-9/BI)

=> d ide can 126 1-3

L26 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2002 ACS

RN **326622-01-9** REGISTRY

CN L-Phenylalanine, L-asparaginyl-L-isoleucyl-L-.alpha.-aspartyl-L-prolyl-L-seryl-L-.alpha.-aspartyl-L-seryl-L-.alpha.-glutamyl-L-isoleucyl-L-phenylalanyl-L-tyrosyl-L-asparaginyl-L-glutamyl-L-lysyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 9: PN: JP2001046066 SEQID: 12 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C82 H117 N19 O28


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:192229

L26 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2002 ACS

RN **268728-68-3** REGISTRY

CN L-Valine, L-histidylglycyl-L-histidyl-L-.alpha.-glutamyl-L-glutaminyl-L-glutaminyl-L-histidylglycyl-L-leucylglycyl-L-histidylglycyl-L-histidyl-L-lysyl-L-phenylalanyl-L-lysyl-L-leucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-leucyl-L-.alpha.-glutamyl-L-histidyl-L-glutaminylglycylglycyl-L-histidyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C135 H197 N47 O42

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 1-D



PAGE 1-E



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:802

L26 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2002 ACS


RN 268728-65-0 REGISTRY

CN L-Valine, L-leucyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-.alpha.-  
aspartyl-L-leucyl-L-.alpha.-glutamyl-L-histidyl-L-glutaminylglycylglycyl-L-  
histidyl- (9CI) (CA INDEX NAME)


FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C55 H83 N17 O22  
 SR CA  
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:802

=>  
 =>

=> fil hcaplus  
 FILE 'HCAPLUS' ENTERED AT 17:24:12 ON 26 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Oct 2002 VOL 137 ISS 18  
 FILE LAST UPDATED: 25 Oct 2002 (20021025/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=>  
 =>

=> d stat que 125 nos  
 L1 STR  
 L11 39893 SEA FILE=REGISTRY SSS FUL L1  
 L13 STR  
 L14 STR  
 L17 STR  
 L18 282 SEA FILE=REGISTRY SUB=L11 SSS FUL (L17 AND L13) NOT L14  
 L19 231 SEA FILE=HCAPLUS ABB=ON PLU=ON L18  
 L25 22 SEA FILE=HCAPLUS ABB=ON PLU=ON L19(L) (?DRUG? OR ?MEDIC? OR ?PHARM? OR ?THERAP?)

=>  
 =>

=> d ibib abs hitrn 125 1-22

L25 ANSWER 1 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:757301 HCAPLUS  
 DOCUMENT NUMBER: 137:243132  
 TITLE: Human transport protein 20.24 and its cDNA and therapeutic use thereof  
 INVENTOR(S): Mao, Yumin; Xie, Yi  
 PATENT ASSIGNEE(S): Bode Gene Development Co., Ltd., Shanghai, Peop. Rep. China  
 SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 33 pp.  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1331129	A	20020116	CN 2000-116734	20000626

AB The invention provides cDNA sequences of a novel human transport protein 20.24 (mol. wt. in kDa, also called TP20.24) cloned from human embryonic brain. The invention also relates to constructing the cloned gene expression vectors to prep. its recombinant protein using E. coli or eukaryotic cells. Methods of expressing and prepg. the above recombinant protein and its antibody are described. The mRNA expression profile in various normal or tumor cell lines and tissues is also provided. The invention further relates to applications of related gene or protein products for the treatment of related diseases, such as cancer, blood diseases, HIV infection, immune diseases and inflammation. Methods for screening for related analogs, agonists, inhibitors and antagonists to be used as therapeutic drugs are also described.

IT 460333-14-6

RL: PRP (Properties)

(unclaimed sequence; human transport protein 20.24 and its cDNA and **therapeutic** use thereof)

L25 ANSWER 2 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:676325 HCAPLUS

DOCUMENT NUMBER: 137:231363

TITLE: Computerized methods for identifying T cell epitope and use for preparing protein or antibody therapeutic agent with reduced immunogenicity

INVENTOR(S): Carr, Francis J.; Carter, Graham; Jones, Tim; Williams, Stephen; Hamilton, Anita

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069232	A2	20020906	WO 2002-EP1688	20020218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2001-103954 A 20010219  
EP 2001-105777 A 20010308  
EP 2001-106536 A 20010315  
EP 2001-106538 A 20010315  
EP 2001-106899 A 20010320  
EP 2001-107012 A 20010320  
EP 2001-107568 A 20010327  
EP 2001-110220 A 20010425  
EP 2001-113228 A 20010530  
EP 2001-124965 A 20011019  
EP 2001-126859 A 20011112

AB Computerized method, with Bohm scoring function modified to include 12-6 van der Waal's ligand protein energy repulsive term and ligand conformational energy term based on MHC class II mol., is used for

identification of T-cell epitopes, that give rise to an immune reaction in a living host. By means of this novel method biol. compds. can be generated which have a no or at least a reduced immunogenicity when exposed to the immune system of a given species and compared with the relevant non-modified entity. Thus the invention relates also to novel biol. mols., esp. proteins and antibodies, obtained by the method according to the invention.

L25 ANSWER 3 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:658159 HCAPLUS

DOCUMENT NUMBER: 137:200267

TITLE: Fusion proteins comprising immunoglobulin and target antigen with reduced T cell epitope and immunogenicity for therapeutic use

INVENTOR(S): Gillies, Stephen; Carr, Francis J.; Jones, Tim; Carter, Graham; Hamilton, Anita; Williams, Stephen; Hanlon, Marian; Watkins, John; Baker, Matthew; Way, Jeffrey C.

PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066514	A2	20020829	WO 2002-EP1690	20020218

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: EP 2001-103955 A 20010219  
EP 2001-108291 A 20010405

AB The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified mol. when exposed to a species in vivo. The invention relates, above all, to novel Ig fusion proteins which essentially consist of an Ig mol. or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biol. active non-Ig mol., preferably a polypeptide or protein or a biol. active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunol. target mol. which elicits biol. or pharmacol. efficacy. The mols. of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biol. activity as compared with the non-altered mols. The changes are made in regions of the mols. which are identified as T-cell epitopes, which contribute to an immune reaction in a living host. Thus, the invention also relates to a novel method of making such fusion proteins by identifying said epitopes comprising calcn. of T-cell epitope values for MHC Class II mol. binding sites in a peptide by computer-aided methods.

IT 445043-30-1

RL: PRP (Properties)

(unclaimed sequence; fusion proteins comprising Ig and target antigen with reduced T cell epitope and immunogenicity for **therapeutic**



use)

L25 ANSWER 4 OF 22 HCAPLUS COPYRIGHT 2002 ACS  
 ACCESSION NUMBER: 2002:638210 HCAPLUS  
 DOCUMENT NUMBER: 137:196735  
 TITLE: Differentially expressed sequences and proteins for  
 use in the therapy and diagnosis of human lung cancer  
 INVENTOR(S): Kalos, Michael D.; McNeill, Patricia D.; Retter, Marc  
 W.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 276 pp., Cont.-in-part of U.S.  
 Ser. No. 735,705.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 8  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002052329	A1	20020502	US 2000-735705	20001212
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2000-735705	A2 20001212
			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			US 2001-850716	A 20010507
			US 2001-897778	A 20010628

WO 2001-US21065 W 20010628

AB Lung-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly lung cancer, are identified. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IT 387817-80-3

RL: ANT (Analyte); BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(L523S peptide; differentially expressed sequences and proteins for use in **therapy** and diagnosis of human lung cancer)

IT 387817-64-3

RL: ANT (Analyte); BSU (Biological study, unclassified); BUU (Biological use, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(L773P peptide; differentially expressed sequences and proteins for use in **therapy** and diagnosis of human lung cancer)

L25 ANSWER 5 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:368697 HCAPLUS

DOCUMENT NUMBER: 136:382012

TITLE: Prostate-specific genes and proteins and their use for cancer diagnosis, drug screening, and vaccines

INVENTOR(S): Sun, Yongming; Recipon, Herve; Chen, Sei-Yu; Liu, Chenghua

PATENT ASSIGNEE(S): Diadexus, Inc., USA

SOURCE: PCT Int. Appl., 267 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038810	A2	20020516	WO 2001-US47001	20011106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002035164	A5	20020521	AU 2002-35164	20011106
---------------	----	----------	---------------	----------

PRIORITY APPLN. INFO.:	US 2000-246109P	P	20001106
------------------------	-----------------	---	----------

WO 2001-US47001	W	20011106
-----------------	---	----------

AB The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic prostate cells, including fragments, variants and derivs. of the nucleic acids and polypeptides. Specifically, 135 DNAs and 105 proteins (or fragments) are disclosed. The mRNA tissue expression profiles of some clones are studied indicating a pattern of the predominant expression in prostate and overexpression in prostate cancer. The chromosome locations of some clones are also provided. The present invention also relates to antibodies to the

polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compns. comprising the nucleic acids, polypeptides, antibodies, variants, derivs., agonists and antagonists of the invention and methods for the use of these compns. These uses include identifying, diagnosing, monitoring, staging, imaging and treating prostate cancer and non-cancerous disease states in prostate tissue, identifying prostate tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides if the invention. The uses also include gene therapy, prodn. of transgenic animals and cells, and prodn. of engineered prostate tissue for treatment and research.

## IT 425604-38-2P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence of prostate-specific protein fragment;  
prostate-specific genes and proteins and use for cancer diagnosis,  
drug screening, and vaccines)

L25 ANSWER 6 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:332673 HCAPLUS

DOCUMENT NUMBER: 136:354185

TITLE: Lung tumor-specific antigen, chimeric antigens,  
polynucleotides, and antibodies for therapy and  
diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur,  
Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li,  
Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.;  
Henderson, Robert A.; McNeill, Patricia D.; Fanger,  
Neil

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S.  
Ser. No. 685,696.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002052329	A1	20020502	US 2000-735705	20001212
US 6312695	B1	20011106	US 1998-123912	19980727
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002115139	A1	20020822	US 2001-850716	20010507
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,				

PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
 UG, US, UZ, VN, YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

## PRIORITY APPLN. INFO.:

US 1998-40802 A2 19980318  
 US 1998-123912 A2 19980727  
 US 1998-221107 A2 19981222  
 US 1999-285479 A2 19990402  
 US 1999-466396 A2 19991217  
 US 1999-476496 A2 19991230  
 US 2000-480884 A2 20000110  
 US 2000-510376 A2 20000222  
 US 2000-542615 A2 20000404  
 US 2000-606421 A2 20000628  
 US 2000-630940 A2 20000802  
 US 2000-643597 A2 20000821  
 US 2000-662786 A2 20000915  
 US 2000-685696 A2 20001009  
 US 2000-735705 A2 20001212  
 US 2001-850716 A 20010507  
 US 2001-897778 A 20010628  
 WO 2001-US21065 W 20010628

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

## IT 387817-64-3 387817-80-3

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lung tumor-specific antigen, chimeric antigens, polynucleotides, and antibodies for **therapy** and diagnosis of lung cancer)

L25 ANSWER 7 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:314975 HCAPLUS

DOCUMENT NUMBER: 136:320410

TITLE: Novel secreted proteins LP102, LP187, LP190 and LP241, their cDNAs and therapeutic and diagnostic use thereof

INVENTOR(S): Lu, Deshun; Song, Ho Yeong; Su, Eric Wen; Wang, He

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002032939	A2	20020425	WO 2001-US27759	20011010
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,			

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-241813P P 20001019

AB The invention provides protein and cDNA sequences for four novel human secreted proteins, named as LP102, LP187, LP190 and LP241, which are called LP protein in general. LP102 is a new member of the ADAM family (contg. "A Disintegrin And Metalloprotease" domain, also known as adamalysin) based on sequence similarity. LP102 also shares sequence homol. with human and mouse PH30 .beta. chain sperm protein and tMDC III. LP187 has sequence homol. with mouse liver cancer-originated growth factor (LCGF), lung growth factor variant (LGF), lens epithelium-derived growth factor (LEDGF), and hepatoma-derived growth factor (HDGF). LP190 is a sequence homolog of carboxypeptidase A and its mRNA tissue expression profile is also provided. LP190 gene is localized to chromosome 7q31. LP241 has sequence similarity with IGF binding protease. The invention also relates to vectors for recombinant expression of the cloned genes, host cells, and antibodies directed to said LP protein. The invention provides the use of polypeptide and polynucleotide in a method for treatment of various kinds of disease.

IT 413567-18-7

RL: PRP (Properties)

(unclaimed sequence; novel secreted proteins LP102, LP187, LP190 and LP241, their cDNAs and **therapeutic** and diagnostic use thereof)

L25 ANSWER 8 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:142913 HCAPLUS

DOCUMENT NUMBER: 136:196180

TITLE: Detecting enzyme activity in an immunoassay using protein or peptide substrate

INVENTOR(S): Kraemer, Joachim; Mander, Thomas; Peiker, Christine; Henco, Karsten

PATENT ASSIGNEE(S): Evotec Biosystems A.-G., Germany

SOURCE: PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002014543	A2	20020221	WO 2001-EP9354	20010813
W:				
			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
EP 1182263	A1	20020227	EP 2000-117457	20000811
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
EP 1199370	A1	20020424	EP 2000-122707	20001018
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL	
EP 1217078	A1	20020626	EP 2000-128176	20001221
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR	
AU 2001093768	A5	20020225	AU 2001-93768	20010813
PRIORITY APPLN. INFO.:			EP 2000-117457	A 20000811

EP 2000-118431 A 20000824  
 EP 2000-122707 A 20001018  
 EP 2000-128176 A 20001221  
 WO 2001-EP9354 W 20010813

AB The invention relates to a process for detecting enzyme activity in an immunoassay, in particular to a process for detecting dephosphorylation of phosphoserine or phosphothreonine by the activity of a protein phosphatase as well as to a process for detecting acetyltransferase or deacetylase activity in an immunoassay. The immunoassay comprises the following steps: (a) providing a protein, a peptide, or a deriv. thereof comprising the sequence motif -Z-X-Y- or -Y-X-Z- wherein Z = an amino acid to be modified by the enzyme, X = a sequence of amino acids, preferably between 0 and 1000 amino acids which may be the same or different, Y = a discrimination enhancer for the binding to an antibody, as a substrate for the enzyme; (b) incubating the protein, peptide, or deriv. thereof with the enzyme to form a modified protein, peptide, or deriv. thereof; (c) adding an antibody discriminating the modified Z from the unmodified Z position of said protein, peptide, or deriv. thereof, said discrimination being mediated by the presence of the affinity enhancer; and (d) detecting the enzyme activity. The invention relates further to a kit for carrying out the assay and to a luminescently labeled ligand. The assay could be used for screening modulators for enzyme activity.

IT 400633-36-5

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (JNK1, JNK2 or JNK3 active site loop; detecting enzyme activity in immunoassay using protein or peptide substrate in relation to **drug** screening)

IT 400633-38-7 400633-40-1 400633-41-2

RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)  
 (detecting enzyme activity in immunoassay using protein or peptide substrate in relation to **drug** screening)

L25 ANSWER 9 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:72121 HCAPLUS

DOCUMENT NUMBER: 136:130773

TITLE: Substrates and assays for .beta.-secretase activity and their use in drug screening

INVENTOR(S): Yan, Riqian; Tomasselli, Alfredo G.; Gurney, Mark E.; Emmons, Thomas L.; Bienkowski, Michael Jerome; Heinrikson, Robert L.

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 188 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006306	A2	20020124	WO 2001-US23035	20010719

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-219795P P 20000719

US 2001-275251P P 20010312

AB The present invention is directed to novel substrates for .beta.-secretase. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a .beta.-secretase cleavage site. Methods and compns. for making and using the peptides are disclosed. Thus, peptides such as biotin-KEISEISY-EVEFR(Cys-Oregon Green)KK may be used for high-throughput screening of .beta.-secretase modulating compds. .beta.-Secretase cleaves these peptides at rates greater than the rates for peptides contg. the human APP .beta.-secretase cleavage sequence.

IT 393092-38-1

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(.beta.-secretase cleavage site, substrates contg.; substrates and assays for .beta.-secretase activity and their use in **drug** screening)

L25 ANSWER 10 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2002:10236 HCAPLUS

DOCUMENT NUMBER: 136:101081

TITLE: Compositions and methods for the therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Wang, Aijun; Skeiky, Yasir A. W.; Li, Samuel X.; Kalos, Michael D.; Henderson, Robert A.; Mcneill, Patricia D.; Fanger, Neil; Retter, Marc W.; Marnerakis, Margarita; Fanger, Gary Richard; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Peckham, David W.

PATENT ASSIGNEE(S): Corixa Corp., USA

SOURCE: PCT Int. Appl., 374 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
AU 2001073149	A5	20020108	AU 2001-73149	20010628
PRIORITY APPLN. INFO.:			US 2000-606421	A 20000628
			US 2000-630940	A 20000802
			US 2000-643597	A 20000821
			US 2000-662786	A 20000915
			US 2000-685696	A 20001009
			US 2000-735705	A 20001212
			US 2001-850716	A 20010507
			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402

US 1999-466396 A2 19991217  
 US 1999-476496 A2 19991230  
 US 2000-480884 A2 20000110  
 US 2000-510376 A2 20000222  
 US 2000-542615 A2 20000404  
 WO 2001-US21065 W 20010628

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IT 387817-64-3 387817-80-3

RL: PRP (Properties)

(unclaimed sequence; compns. and methods for the **therapy** and diagnosis of lung cancer)

L25 ANSWER 11 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:903794 HCAPLUS

DOCUMENT NUMBER: 136:58784

TITLE: Encapsulation of plasmid DNA (Lipogenes) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes

INVENTOR(S): Boulikas, Teni

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001093836	A2	20011213	WO 2001-US18657	20010608
WO 2001093836	A3	20021003		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-210925P P 20000609

AB A method is disclosed for encapsulating plasmids, oligonucleotides or neg.-charged drugs into liposomes having a different lipid compn. between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after i.v. injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid mols. and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also contg. four or more histidine residues or NLS at their one end. The encapsulated mols. display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or neg.-charged drugs with other anti-neoplastic drugs (the pos.-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of the encapsulated plasmids,



oligonucleotides or neg.-charged drugs with HSV-tk plus encapsulated ganciclovir.

IT **379720-53-3**

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(encapsulation of plasmid DNA (Lipogenes) and **therapeutic** agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes)

L25 ANSWER 12 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:545482 HCAPLUS

DOCUMENT NUMBER: 135:132452

TITLE: .beta.-Turn peptidomimetic cyclic compounds for neurotrophin receptor agonists and antagonists, and therapeutic use thereof

INVENTOR(S): Saragovi, Horacio Uri; Burgess, Kevin

PATENT ASSIGNEE(S): McGill University, Can.; The Texas A & M University System

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001052843	A1	20010726	WO 2001-CA43	20010118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-176482P P 20000118

OTHER SOURCE(S): MARPAT 135:132452

AB Proteolytically stable small mol. .beta.-turn peptidomimetic compds. have been identified as agonists or antagonists of neurotrophin receptors, such as TrkA. A compd. of particular interest binds the Ig-like C2 region of the extracellular domain of TrkA, competes the binding of another TrkA ligand, affords selective trophic protection to TrkA-expressing cell lines and neuronal primary cultures, and induces the differentiation of primary neuronal cultures. The small .beta.-turn peptidomimetic compds. of the invention can activate a tyrosine kinase neurotrophin receptor that normally binds a relatively large protein ligand. Such compds. that bind the extracellular domain of Trk receptors are useful pharmacol. agents to address disorders where Trk receptors play a role, by targeting populations selectively.

IT **351974-60-2**

RL: PRP (Properties)

(unclaimed sequence; .beta.-Turn peptidomimetic cyclic compds. for neurotrophin receptor agonists and antagonists, and **therapeutic** use thereof)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 13 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:78407 HCAPLUS

DOCUMENT NUMBER: 134:143865

TITLE: CPEB-derived peptides blocking Eg2 kinase activity and

their therapeutic uses  
 INVENTOR(S): Richter, Joel D.; Mendez, Raul  
 PATENT ASSIGNEE(S): University of Massachusetts, USA  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001007466	A1	20010201	WO 2000-US20254	20000721
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1203013	A1	20020508	EP 2000-948960	20000721
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

PRIORITY APPLN. INFO.: US 1999-144903P P 19990721  
 WO 2000-US20254 W 20000721

AB Disclosed are peptides (blocking polypeptides) that inhibit kinase Eg2 activity, thereby inhibiting activation of the protein known as CPEB. Eg2 is a member of the Aurora family of protein kinases and is known to play a role in cell signaling, early animal development and embryogenesis and, in the brain, can mediate synaptic plasticity. The peptides comprise a conserved region of CPEB, an RNA-binding protein involved in polyadenylation modulation, with the structure Leu-Asp-X-Arg, where X = Gly, Ala, Val, Leu, Ile, Met, Cys, Ser, Thr. Accordingly, the blocking polypeptides of the invention can be used to inhibit and control Eg2 activity. Inhibition of Eg2 activity can be used to treat cancer. DNAs encoding the CPEB-polypeptide, vectors, and cells contg. the DNA, and CPEB-like specific antibodies are also disclosed.

IT 321897-51-2 321897-55-6 321897-64-7  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CPEB-derived peptides blocking Eg2 kinase activity and their  
**therapeutic** uses)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 14 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:708149 HCAPLUS

DOCUMENT NUMBER: 133:361833

TITLE: Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes

AUTHOR(S): Winer, Shawn; Gunaratnam, Lakshman; Astsatourov, Igor; Cheung, Roy K.; Kubiak, Violetta; Karges, Wolfram; Hammond-McKibben, Denise; Gaedigk, Roger; Graziano, Daniel; Trucco, Massimo; Becker, Dorothy J.; Dosch, H.-Michael

CORPORATE SOURCE: Department of Immunology, Infection, Injury and Repair Program, The Hospital for Sick Children, Research Institute, University of Toronto, Toronto, ON, Can.

SOURCE: Journal of Immunology (2000), 165(7), 4086-4094

CODEN: JOIMA3; ISSN: 0022-1767

PUBLISHER: American Association of Immunologists

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cross-reactive T cells that recognize both Tep69 (dominant nonobese diabetic (NOD) T cell epitope in ICA69 (islet cell autoantigen of 69 kDa))

and ABBOS (dominant NOD T cell epitope in BSA) are routinely generated during human and NOD mouse prediabetes. Here we analyzed how systemic administration of these mimicry peptides affects progressive autoimmunity in adoptively transferred and cyclophosphamide-accelerated NOD mouse diabetes. These models were chosen to approx. mid to late stage prediabetes, the typical status of probands in human intervention trials. Unexpectedly, high dose (100 .mu.g) i.v. ABBOS prevented, while Tep69 exacerbated, disease in both study models. Peptide effects required cognate recognition of endogenous self-Ag, because both treatments were ineffective in ICA69null NOD congenic mice adoptively transferred with wild-type, diabetic splenocytes. The affinity of ABBOS for NOD I-Ag7 was orders of magnitude higher than that of Tep69. This explained 1) the expansion of the mimicry T cell pool following i.v. Tep69, 2) the long-term unresponsiveness of these cells after i.v. ABBOS, and 3) pptn. of the disease after low dose i.v. ABBOS. Disease pptn. and prevention in mid to late stage prediabetes are thus governed by affinity profiles and doses of therapeutic peptides. ABBOS or ABBOS analogs with even higher MHC affinity may be candidates for exptl. intervention strategies in human prediabetes, but the dose translation from NOD mice to humans requires caution.

IT 197894-09-0P

RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(ovalbumin; peptide dose, MHC affinity, and target self-antigen expression are crit. for effective **immunotherapy** of nonobese diabetic mouse prediabetes)

REFERENCE COUNT: 66 THERE ARE 66 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 15 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:368424 HCAPLUS

DOCUMENT NUMBER: 133:12727

TITLE: Peptidic pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease

INVENTOR(S): Pessi, Antonello; Ingallinella, Paola; Bianchi, Elisabetta

PATENT ASSIGNEE(S): Istituto di Ricerche di Biologia Molecolare p Angeletti Spa, Italy

SOURCE: PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000031129	A1	20000602	WO 1999-EP9207	19991124
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1144446	A1	20011017	EP 1999-972641	19991124
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: GB 1998-25946 A 19981126  
WO 1999-EP9207 W 19991124

OTHER SOURCE(S): MARPAT 133:12727

AB Peptidic inhibitors of hepatitis C virus NS3 protease are disclosed which are based on the P and P' regions of the natural substrate. The P' part of the inhibitor is optimized to achieve max. binding energy through interaction with the S' region of the enzyme. By selecting amino acids such that the inhibitor is substantially not cleavable by the NS3 protease, inhibitors having potency in the low nanomolar to sub-nanomolar range can be achieved.

IT 272435-80-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(peptidic **pharmaceutical** compds. for inhibition of hepatitis C virus NS3 protease)

IT 272435-83-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(peptidic **pharmaceutical** compds. for inhibition of hepatitis C virus NS3 protease)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 16 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:304278 HCAPLUS

DOCUMENT NUMBER: 132:331338

TITLE: Cloning, sequences and therapeutic use of protein kinases of the casein kinase I HRR25 family of yeast and human

INVENTOR(S): Hoekstra, Merl F.

PATENT ASSIGNEE(S): The Salk Institute for Biological Studies, USA

SOURCE: U.S., 66 pp., Cont.-in-part of U.S. Ser. No. 8,001, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6060296	A	20000509	US 1994-185359	19940121
CA 2158750	AA	19950727	CA 1995-2158750	19950123
CA 2158750	C	19990413		
CA 2180750	AA	19950727	CA 1995-2180750	19950123
WO 9519993	A1	19950727	WO 1995-US955	19950123
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 690876	A1	19960110	EP 1995-909318	19950123
EP 690876	B1	19990623		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08509504	T2	19961008	JP 1995-519735	19950123
JP 3091769	B2	20000925		
AT 181559	E	19990715	AT 1995-909318	19950123
US 5627064	A	19970506	US 1995-447500	19950523
US 5686412	A	19971111	US 1995-454097	19950530
US 5756289	A	19980526	US 1995-453866	19950530

PRIORITY APPLN. INFO.: US 1991-728783 B2 19910703  
US 1993-8001 B2 19930121  
US 1994-185359 A 19940121  
WO 1995-US955 W 19950123

AB HRR25-like protein kinase mutant and wild-type genes encoding polypeptides of the 'casein kinase I' class which possess protein kinase and/or DNA recombination/repair promoting functional capabilities are disclosed.

Identification, isolation and genomic and cDNA sequences of yeast and human HRR25-like protein kinases are disclosed. The HRR25-like protein kinases are useful in screening compds. which may affect DNA double-strand break repair activity. Also disclosed are methods using the polynucleotides in cell-proliferative disorders.

IT **168552-66-7**

RL: PRP (Properties)

(unclaimed sequence; cloning, sequences and **therapeutic** use of protein kinases of the casein kinase I HRR25 family of yeast and human)

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 17 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:409951 HCAPLUS

DOCUMENT NUMBER: 127:107902

TITLE: Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis

AUTHOR(S): Verheijden, Gijs F. M.; Rijnders, Antonius W. M.; Bos, Ebo; Coenen-De Roo, Christina J. J.; Van Staveren, Catherina J.; Miltenburg, Andre M. M.; Meijerink, Jan H.; Elewaut, Dirk; De Keyser, Filip; Veys, Eric; Boots, Annemieke M. H.

CORPORATE SOURCE: NV Organon, Oss, Neth.

SOURCE: Arthritis & Rheumatism (1997), 40(6), 1115-1125

CODEN: ARHEAW; ISSN: 0004-3591

PUBLISHER: Lippincott-Raven

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The objective of this study was to identify a cartilage-derived autoantigen that is relevant to the rheumatoid arthritis (RA) disease process. A DR4 (DRB1\*0401) peptide binding motif was used for the selection of potential self reactive peptides within human cartilage glycoprotein-39 (HC gp-39), a protein that is differentially expressed at the site of chronic inflammation. Synthetic peptides accommodating the motif were tested for binding the RA-assocd. DR4 (DRB1\*0401) mols. High-affinity binders were then tested for their capacity to stimulate peripheral blood mononuclear cell responses in RA patients or healthy donors. To assess the arthritogenic nature of native HC gp-39, the protein was injected into BALB/c mice. HC gp-39-derived motif-based peptides were selectively recognized by peripheral blood T cells from RA patients. Injection of the intact protein into BALB/c mice resulted in immunity to HC gp-39, which was found to be assocd. with the development of a chronic, relapsing arthritis. Moreover, inhalation of the protein led to tolerization of antigen-specific T cells and to suppression of HC gp-39-induced arthritis. These data indicate that HC gp-39 is a target of the immune response in RA. Consequently, HC gp-39 is a candidate for antigen-specific immunotherapy.

IT **178274-48-1**

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis and its use in **immunotherapy**)

L25 ANSWER 18 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:265581 HCAPLUS

DOCUMENT NUMBER: 126:248257

TITLE: Manufacture and purification of the hepatitis C virus NS3 proteinase and screening of therapeutic inhibitors

INVENTOR(S): Steinkuehler, Christian; Pessi, Antonello; Bianchi, Elisabetta; Taliani, Marina; Tomei, Licia; Urbani, Andrea; De, Francesco Raffaele; Narjes, Frank

PATENT ASSIGNEE(S): Istituto Di Ricerche Di Biologia Molecolare P. Ang,

Italy; Steinkuehler, Christian; Pessi, Antonello;  
 Bianchi, Elisabetta; Taliani, Marina; Tomei, Licia;  
 Urbani, Andrea; De Francesco, Raffaele; Narjes, Frank  
 SOURCE: PCT Int. Appl., 69 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708304	A2	19970306	WO 1996-IT163	19960820
WO 9708304	A3	19970522		
W: AU, BR, CA, CN, JP, RU, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2228265	AA	19970306	CA 1996-2228265	19960820
AU 9666686	A1	19970319	AU 1996-66686	19960820
AU 716379	B2	20000224		
EP 846164	A2	19980610	EP 1996-926574	19960820
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1193997	A	19980923	CN 1996-196406	19960820
JP 10511556	T2	19981110	JP 1996-510082	19960820
BR 9610039	A	19990706	BR 1996-10039	19960820
JP 3310298	B2	20020805	JP 1997-510082	19960820
US 6197536	B1	20010306	US 1998-11961	19980223
PRIORITY APPLN. INFO.: IT 1995-RM573 A 19950822				
WO 1996-IT163 W 19960820				

AB Methods for the manuf., assay, and purifn. of the hepatitis C virus NS3 proteinase for use in characterization of the structure, function, and properties of the enzyme and the screening and development of inhibitors. Assay substrates and conditions for high throughput screening of inhibitors of the enzyme are described. Expression vectors for manuf. of the enzyme in culture are described. Manuf. of the enzyme in Escherichia coli and in insect cell culture (Sf9 cells) using a baculovirus vector is described. Identification of peptide substrates and the synthesis of depsiptide analogs is described.

IT 182171-21-7 182171-22-8 182171-23-9  
 182171-30-8 188530-09-8 188530-10-1  
 188530-11-2 188530-12-3 188530-13-4  
 188530-15-6 188530-17-8 188530-18-9

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)  
 (as substrate for NS3 proteinase; manuf. and purifn. of hepatitis C virus NS3 proteinase and screening of **therapeutic** inhibitors)

L25 ANSWER 19 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1997:168534 HCAPLUS

DOCUMENT NUMBER: 126:153178

TITLE: Single-chain analogs of the TGF-.beta. superfamily (morphons) prepared as fusion products human protein domains and their therapeutic uses

INVENTOR(S): Keck, Peter C.; Smart, John E.

PATENT ASSIGNEE(S): Creative Biomolecules, Inc., USA

SOURCE: PCT Int. Appl., 132 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 9640771 A1 19961219 WO 1996-US9293 19960606  
W: AU, CA, JP  
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE  
US 6040431 A 20000321 US 1995-478097 19950607  
CA 2223292 AA 19961219 CA 1996-2223292 19960606  
AU 9661570 A1 19961230 AU 1996-61570 19960606  
AU 717811 B2 20000330  
EP 833844 A1 19980408 EP 1996-919162 19960606  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI  
JP 11510686 T2 19990921 JP 1996-501647 19960606  
PRIORITY APPLN. INFO.: US 1995-478097 A 19950607  
WO 1996-US9293 W 19960606

AB Disclosed is a family of single-chain polypeptide constructs designed to agonize or mimic members of the TGF-.beta. superfamily by binding to a cell surface receptor complementary to the superfamily member. The single-chain constructs of the invention called "morphons" contain in a single biol. active subunit interacting finger and heel regions which together define a tertiary protein structure complementary to the ligand binding surface of a receptor that binds a TGF-.beta. superfamily member. Also disclosed are truncated versions of the morphon constructs. Methods are disclosed for making and using single-chain morphons that have binding affinity for predetd. receptors of the TGF-.beta. superfamily.

IT **186378-41-6DP**, fusion products  
RL: BPN (Biosynthetic preparation); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(amino acid sequence; single-chain analogs of TGF-.beta. superfamily (morphons) prepd. as fusion products human protein domains and their **therapeutic** uses)

L25 ANSWER 20 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1996:397369 HCAPLUS  
DOCUMENT NUMBER: 125:49310  
TITLE: Novel peptides derived from the articular cartilage autoantigen HC gp-39 for use in immunotherapy of autoimmune diseases  
INVENTOR(S): Boots, Anna Maria Helena; Verheijden, Gijsbertus Franciscus Maria  
PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.  
SOURCE: PCT Int. Appl., 37 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9613517	A1	19960509	WO 1995-EP4201	19951025
W: AU, BR, CA, CN, FI, HU, JP, KR, MX, NO, NZ, PL, RU, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
IL 115744	A1	20000716	IL 1995-115744	19951024
AU 9539252	A1	19960523	AU 1995-39252	19951025
AU 696827	B2	19980917		
EP 733065	A1	19960925	EP 1995-937008	19951025
EP 733065	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
HU 74847	A2	19970228	HU 1996-1401	19951025
HU 218027	B	20000528		
JP 09507861	T2	19970812	JP 1995-514306	19951025
BR 9506377	A	19970916	BR 1995-6377	19951025
CN 1168677	A	19971224	CN 1995-190944	19951025
AT 177756	E	19990415	AT 1995-937008	19951025

ES 2130672	T3	19990701	ES 1995-937008	19951025
RU 2178797	C2	20020127	RU 1996-115937	19951025
PL 183761	B1	20020731	PL 1995-315198	19951025
ZA 9509123	A	19970123	ZA 1995-9123	19951027
US 5736507	A	19980407	US 1996-619645	19960325
FI 9602619	A	19960625	FI 1996-2619	19960625
NO 9602695	A	19960626	NO 1996-2695	19960626
PRIORITY APPLN. INFO.:			EP 1994-203128	A 19941027
			EP 1995-200886	A 19950407
			WO 1995-EP4201	W 19951025

AB Novel peptides derived from the autoantigen HC gp-39 including at least one of the fragments FGRSFTLAS, FTLASSETC, YDDQESVKS or FSKIASNTQ are described for use in the induction of immune tolerance in the treatment of autoimmune disease. The peptides resemble MHC Class II restricted T-cell epitopes present on the autoantigen HC gp-39 in articular cartilage. HC gp-39 and these peptides can be used in antigen-specific treatment of articular cartilage destruction in autoimmune diseases to induce tolerance of the immune system. The autoantigen HC gp-39 and these peptides are also suitable to induce arthritis in non-human animals, preferably mice. The invention furthermore relates to pharmaceutical compns. comprising said autoantigen and/or said peptides, a diagnostic method for the detection of autoreactive T cells in a test sample and test kits to be used in said method. The use of these peptides to induce immune tolerance in mice is demonstrated.

IT **178274-48-1D**, analogs, derivs.

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel peptides derived from articular cartilage autoantigen HC gp-39 for use in **immunotherapy** of autoimmune diseases)

L25 ANSWER 21 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:907626 HCAPLUS

DOCUMENT NUMBER: 124:30420

TITLE: Preparation of antigen peptide compound and immunoassay method for hepatitis C virus (HCV) antibody

INVENTOR(S): Kumazawa, Toshiaki

PATENT ASSIGNEE(S): SRL, Inc., Japan

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9511918	A1	19950504	WO 1994-JP1823	19941028
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, KG, KR, KZ, LK, LT, LV, MD, MG, MN, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
JP 07179493	A2	19950718	JP 1994-207695	19940831
AU 9480038	A1	19950522	AU 1994-80038	19941028
EP 729973	A1	19960904	EP 1994-931183	19941028
R: DE, GB, SE				
US 5885771	A	19990323	US 1996-617929	19960424
PRIORITY APPLN. INFO.:			JP 1993-272864	19931029
			JP 1994-207695	19940831
			WO 1994-JP1823	19941028

AB A hepatitis C virus (HCV) antibody in a specimen is assayed by immunoassay



utilizing a specific binding affinity between an antigen peptide compd. having the following amino acid sequence, e.g., Leu-Ser-Gly-Arg-Pro-Ala-Ile-Val-Pro-Asp-Arg-Glu-Val-Leu-Tyr-Gln-Glu-Phe-Asp-Glu (I) or Val-Asn-Gln-Arg-Ala-Val-Val-Ala-Pro-Asp-Lys-Glu-Val-Leu-Tyr-Glu-Ala-Phe-Asp-Glu (II) and a HCV antibody. This method permits simple and accurate identification of the serotype for a specimen and thereby differentiation between the corresponding genotype (I and II) and genotype (III and IV) of HCV while suppressing the cross reaction or a nonspecific reaction, accurate estn. of a possible therapeutic effect of interferons based on the fact that interferons are less effective for genotype (I and II) (20% effectiveness) of HCV than genotype (III and IV) (80% effectiveness), and simplification of observation about the healing or the progress of treatment of hepatitis C. A total of 10 peptides (5 pair of peptides) including I and II were identified as possible hepatitis C antigens based on known antigenic peptide sequences, a HVC gene sequence, calcn. of hydrophilicity values of the peptide sequences with the consideration that a peptide having a high hydrophilicity value shows antigenicity, and the common amino acid sequences of genotype (I and II) and those of genotype (III and IV). These peptides were prepd. by the solid phase method using an Applied Biosystems 430A peptide synthesizer and N-Boc-protected amino acid sym. anhydrides. A pair of peptides H-Ile-Ile-Leu-Ser-Gly-Arg-Pro-Ala-Ile-Val-Pro-Asp-Arg-Glu-Leu-Leu-Tyr-Gln-Glu-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-His-Leu-Pro-Tyr-Ile-Glu-Gln-Gly-Met-Gln-Leu-Ala-OH and H-Leu-His-Val-Asn-Gln-Arg-Ala-Val-Val-Ala-Pro-Asp-Lys-Glu-Val-Leu-Tyr-Glu-Ala-Phe-Asp-Glu-Met-Glu-Glu-Cys-Ala-Ser-Arg-Ala-Ala-Leu-Ile-Glu-Glu-Gly-Gln-Arg-Ile-Ala-OH each immobilized on microplates detected and distinguished antibodies of serotypes I corresponding to genotype (I and II) and serotype II corresponding to genotype (III and IV) in 83 and 88% accuracy for chronically active hepatitis and chronically persistent hepatitis specimens, resp.

IT 170098-67-6P

RL: ARG (Analytical reagent use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of antigen peptides for immunoassay of hepatitis C virus antibody in interferon **therapy** of hepatitis C virus)

L25 ANSWER 22 OF 22 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 1995:842649 HCAPLUS  
DOCUMENT NUMBER: 123:246823  
TITLE: Hydrophilic signal oligopeptides and methods of therapeutic use  
INVENTOR(S): Rath, Matthias  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 87 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9519568	A1	19950720	WO 1995-US575	19950112
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN			
RW:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
AU 9516810	A1	19950801	AU 1995-16810	19950112

EP 744027            A1    19961127            EP 1995-908522    19950112  
           R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
 AU 9881834           A1    19981008            AU 1998-81834      19980824  
 AU 735298            B2    20010705

## PRIORITY APPLN. INFO.:

US 1994-182248    A    19940114  
 WO 1995-US575    W    19950112

AB    The instant invention is directed to a method of identifying signal oligopeptides through the use of algorithms, the use of signal oligopeptides as vaccines and as immunogens to produce antibodies. Like the human language, the protein code consists of letters, words, and sentences. The letters (amino acids) and sentences (complete 3-dimensional proteins) have been known previously, but the present discovery identifies the protein words or verbs. These protein verbs are represented by signal oligopeptides which are localized on the surface of the protein and are represented by the hydrophilicity maxima of the protein. These signal oligopeptides are enriched in charged amino acids in a versatile arrangement with neutral spacer amino acids. The sp. signal character of these oligopeptides is detd. by a characteristic combination of conformation and charge within the signal sequence. Sas in human language, the whole sentence (complete 3-dimensional protein) is needed to det. the sp. and complete action of any given protein. In human language eliminating or changing the verb of a sentence renders the whole sentence meaningless. Similarly, blocking the protein code verbs (signal oligopeptides) can be therapeutically used to block the undesired action or interaction of an entire protein. The discovery of the protein code provides the rationale for deciphering the communication code of diseases. Infectious diseases, cancer, cardiovascular and other diseases develop by means of one or more pathogenicity-mediating protein. Blocking the signal oligopeptides of these proteins (e.g., with antibodies) allows the sp. therapeutic interception of a pathol. communication and thereby blocks disease propagation. Some 360 oligopeptides of signal significance are presented.

IT    **168691-23-4 168691-24-5**

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); USES (Uses)  
       (hydrophilic signal oligopeptides and methods of **therapeutic** use)

=> select hit rn 125 1-22  
 E4 THROUGH E40 ASSIGNED

=> fil reg  
 FILE 'REGISTRY' ENTERED AT 17:25:20 ON 26 OCT 2002  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2002 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    25 OCT 2002    HIGHEST RN 466118-13-8  
 DICTIONARY FILE UPDATES:   25 OCT 2002    HIGHEST RN 466118-13-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP

PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=&gt;

=&gt;

=&gt; d his 127

(FILE 'REGISTRY' ENTERED AT 17:23:55 ON 26 OCT 2002)

FILE 'HCAPLUS' ENTERED AT 17:24:12 ON 26 OCT 2002

SELECT HIT RN L25 1-22

FILE 'REGISTRY' ENTERED AT 17:25:20 ON 26 OCT 2002

L27

37 S E4-E40

=&gt; d ide can 127 1-37

L27 ANSWER 1 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **460333-14-6** REGISTRY

CN L-Proline, L-methionyl-L-seryl-L-.alpha.-aspartyl-L-alanyl-L-seryl-L-valyl-  
L-asparaginyl-L-phenylalanyl-L-.alpha.-aspartyl-L-tyrosyl-L-lysyl-L-seryl-  
L-prolyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 8: PN: CN1331129 SEQID: 7 unclaimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C71 H105 N17 O26 S

SR CA



LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:243132

L27 ANSWER 2 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **445043-30-1** REGISTRY

CN L-Phenylalanine, L-leucyl-L-threonyl-L-methionyl-L-.alpha.-aspartyl-L-seryl-L-lysyl-L-lysyl-L-arginyl-L-isoleucylglycyl-L-tryptophyl-L-arginyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 25: PN: WO02066514 PAGE: 50 unclaimed sequence

CN 27: PN: WO02062832 TABLE: 1 claimed protein

CN 76: PN: WO02069232 PAGE: 35 claimed sequence


FS PROTEIN SEQUENCE; STEREOSEARCH

MF C74 H120 N22 O18 S


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER


Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1962 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:231363

REFERENCE 2: 137:200267

REFERENCE 3: 137:164116

L27 ANSWER 3 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **425604-38-2** REGISTRY

CN Glycine, L-lysyl-L-glutaminyL-L-threonyl-L-lysyl-L-leucyl-L-isoleucyl-L-tyrosylglycyl-L-isoleucyl-L-lysyl-L-seryl-L-glutaminyL-L-valyl-L-alanyl-L-phenylalanyl-L-valyl-L-arginyl-L-.alpha.-aspartyl-L-seryl-L-.alpha.-aspartyl-L-lysyl-L-arginyl-L-arginyl-L-leucyl-L-leucyl-L-arginyl-L-seryl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 218: PN: WO0238810 SEQID: 217 claimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C144 H248 N46 O40

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A




PAGE 2-A




PAGE 2-B



PAGE ~~3~~-A



PAGE 3-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)



REFERENCE 1: 136:382012

L27 ANSWER 4 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 413567-18-7 REGISTRY

CN L-Alanine, L-lysyl-L-.alpha.-glutamyl-L-glutaminyl-L-prolyl-L-methionyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-asparaginyl-L-isoleucyl-L-phenylalanyl-L-isoleucyl-L-seryl-L-.alpha.-glutamyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-prolyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 151: PN: W00232939 PAGE: 24 unclaimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C89 H140 N22 O33 S

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:320410

L27 ANSWER 5 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **400633-41-2** REGISTRY

CN L-Alanine, N-[3-[3,6-bis(dimethylamino)xanthylium-9-yl]-4-carboxybenzoyl]-  
L-alanyl-L-arginyl-N6-acetyl-L-lysyl-L-seryl-L-threonyl-L-threonylglycyl-L-  
lysyl-, inner salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 8: PN: W00214543 SEQID: 46 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C64 H92 N16 O18

SR CA


LC STN Files: CA, CAPLUS

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:196180

L27 ANSWER 6 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 400633-40-1 REGISTRY

CN L-Proline, N-[3-[3,6-bis(dimethylamino)xanthylum-9-yl]-4-carboxybenzoyl]-L-alanyl-L-arginyl-L-lysyl-O-phosphono-L-seryl-L-threonyl-L-threonylglycyl-N6-acetyl-L-lysyl-L-alanyl-, inner salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 7: PN: WO0214543 SEQID: 45 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C69 H100 N17 O22 P


SR      CA

LC STN Files: CA, CAPLUS


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:196180

L27 ANSWER 7 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 400633-38-7 REGISTRY

CN L-Proline, N-[3-[3,6-bis(dimethylamino)xanthylum-9-yl]-4-carboxybenzoyl]-  
L-alanyl-L-arginyl-N6-acetyl-L-lysyl-O-phosphono-L-seryl-L-threonyl-L-  
threonylglycyl-L-lysyl-L-alanyl-, inner salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 6: PN: WO0214543 SEQID: 44 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C69 H100 N17 O22 P


SR CA

LC STN Files: CA, CAPLUS


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:196180

L27 ANSWER 8 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **400633-36-5** REGISTRY

CN L-Alanine, N-[3-[3,6-bis(dimethylamino)xanthylum-9-yl]-4-carboxybenzoyl]-L-alanyl-L-arginyl-L-lysyl-O-phosphono-L-seryl-L-threonyl-L-threonylglycyl-L-lysyl-, inner salt (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 5: PN: WO0214543 SEQID: 43 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C62 H91 N16 O20 P


SR CA

LC STN Files: CA, CAPLUS


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:196180

L27 ANSWER 9 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **393092-38-1** REGISTRY

CN L-Alanine, L-.alpha.-aspartyl-L-seryl-L-seryl-L-asparaginyl-L-leucyl-L-.alpha.-glutamyl-L-methionyl-L-threonyl-L-histidyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 8: PN: WO0206306 SEQID: 12 claimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C43 H69 N13 O19 S

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:130773

L27 ANSWER 10 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **387817-80-3** REGISTRY

CN L-Leucine, L-alanyl-L-valyl-L-valyl-L-asparaginyl-L-valyl-L-threonyl-L-tyrosyl-L-seryl-L-seryl-L-lysyl-L-.alpha.-aspartyl-L-glutaminy-L-alanyl-L-arginyl-L-glutaminy-L-alanyl-L-leucyl-L-.alpha.-aspartyl-L-lysyl- (9CI)  
(CA INDEX NAME)

OTHER NAMES:

CN 399: PN: US20020115139 SEQID: 405 claimed protein

CN 403: PN: US20020052329 SEQID: 405 claimed sequence

CN 405: PN: WO0200174 SEQID: 405 unclaimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C95 H160 N28 O32

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A





PAGE 3-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1962 TO DATE)

3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:196735

REFERENCE 2: 136:354185

REFERENCE 3: 136:101081

L27 ANSWER 11 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **387817-64-3** REGISTRY

CN L-Glutamine, L-alanyl-L-alanyl-L-alanyl-L-alanyl-L-seryl-L-threonyl-L-glutaminyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-isoleucyl-L-asparaginyl-L-threonyl-L-glutaminyl-L-arginyl-L-lysyl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 383: PN: US20020115139 SEQID: 389 claimed protein

CN 387: PN: US20020052329 SEQID: 389 claimed sequence

CN 389: PN: WO0200174 SEQID: 389 unclaimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C87 H147 N29 O35

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B



PAGE 3-A



PAGE 4-A



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

3 REFERENCES IN FILE CA (1962 TO DATE)  
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:196735

REFERENCE 2: 136:354185

REFERENCE 3: 136:101081

L27 ANSWER 12 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **379720-53-3** REGISTRY

CN L-Leucine, L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-seryl-L-lysyl-L-arginyl-L-valyl-L-alanyl-L-lysyl-L-arginyl-L-lysyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 380: PN: W00193836 SEQID: 378 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH



MF C55 H102 N20 O17


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A





\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:58784

L27 ANSWER 13 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **351974-60-2** REGISTRY

CN L-Phenylalanine, L-.alpha.-glutamyl-L-lysyl-L-valyl-L-prolyl-L-valyl-L-seryl-L-lysylglycyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-threonyl-L-methionyl-L-.alpha.-aspartyl-L-seryl-L-lysyl-L-lysyl-L-arginyl-L-isoleucylglycyl-L-tryptophyl-L-arginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 12: PN: W00152843 PAGE: 48 unclaimed sequence


FS PROTEIN SEQUENCE; STEREOSEARCH

MF C125 H209 N39 O33 S


SR CA

LC STN Files: CA, CAPLUS


Absolute stereochemistry.




PAGE 1-B



PAGE 1-C





1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:132452

L27 ANSWER 14 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **321897-64-7** REGISTRY

CN L-Serine, L-arginyl-L-seryl-L-seryl-L-arginyl-L-leucyl-L-.alpha.-aspartyl-L-alanyl-L-arginyl-L-seryl-L-isoleucyl-L-leucyl-L-.alpha.-aspartyl-L-seryl-L-arginyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 26: PN: W00107466 SEQID: 8 claimed protein


FS PROTEIN SEQUENCE; STEREOSEARCH

MF C71 H128 N28 O27


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER


Absolute stereochemistry.



PAGE 1-B







1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:143865

L27 ANSWER 15 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 321897-55-6 REGISTRY

CN L-Serine, L-leucyl-L-arginyl-L-seryl-L-seryl-L-arginyl-L-leucyl-L-.alpha.-  
aspartyl-L-seryl-L-arginyl-L-seryl-L-isoleucyl-L-leucyl-L-.alpha.-aspartyl-  
L-seryl-L-arginyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 16: PN: WO0107466 SEQID: 3 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C77 H139 N29 O29

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

\*\*RELATED SEOUENCES AVAILABLE WITH SEOLINK\*\*



Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:143865

L27 ANSWER 16 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **321897-51-2** REGISTRY

CN L-Serine, L-leucyl-L-arginyl-L-seryl-L-seryl-L-arginyl-L-leucyl-L-.alpha.-  
 aspartyl-L-alanyl-L-arginyl-L-seryl-L-isoleucyl-L-leucyl-L-.alpha.-  
 aspartyl-L-seryl-L-arginyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 12: PN: W00107466 SEQID: 3 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C77 H139 N29 O28

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PAGE 1-A



PAGE 1-B



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:143865

L27 ANSWER 17 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **272435-83-3** REGISTRY

CN L-Leucine, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-.beta.-phenylphenylalanyl-L-isoleucyl-3-cyclohexylalanyl-(2S)-2-aminobutanoyl-L-alanyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C63 H90 N12 O17


SR CA

LC STN Files: CA, CAPLUS


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 133:12727


L27 ANSWER 18 OF 37 REGISTRY COPYRIGHT 2002 ACS  
RN **272435-80-0** REGISTRY  
CN L-Lysine, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-prolyl-L-tyrosyl- (9CI) (CA INDEX NAME)  
FS PROTEIN SEQUENCE; STEREOSEARCH  
MF C65 H98 N16 O24 S2  
SR CA  
LC STN Files: CA, CAPLUS

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A






1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:12727


```
L27 ANSWER 19 OF 37  REGISTRY  COPYRIGHT 2002 ACS
RN 197894-09-0  REGISTRY
CN L-Isoleucine, L-.alpha.-glutamyl-L-tyrosyl-L-glutaminyl-L-.alpha.-aspartyl-
L-asparaginyl-L-arginyl-L-valyl-L-seryl-L-phenylalanyl-L-leucylglycyl-L-
histidyl-L-phenylalanyl- (9CI)  (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
MF C79 H113 N21 O23
SR CA
LC STN Files:  CA, CAPLUS, TOXCENTER
```

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 133:361833

REFERENCE 2: 127:330185

L27 ANSWER 20 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **188530-18-9** REGISTRY

CN L-Leucine, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-4,5-didehydro-L-norvalyl-L-alanyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C47 H72 N12 O20 S


SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

L27 ANSWER 21 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **188530-17-8** REGISTRY

CN L-Leucine, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-seryl-L-seryl-L-histidyl-  
(9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C47 H72 N12 O22 S2

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A







1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

L27 ANSWER 22 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **188530-15-6** REGISTRY

CN L-Alanine, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C44 H66 N12 O21 S2


SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A





1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

L27 ANSWER 23 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **188530-13-4** REGISTRY

CN L-Leucine, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-alanyl-L-histidyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C47 H72 N12 O20 S2

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


REFERENCE 1: 126:248257

L27 ANSWER 24 OF 37 REGISTRY COPYRIGHT 2002 ACS  
 RN **188530-12-3** REGISTRY  
 CN L-Leucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)  
 FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C60 H80 N12 O22 S2  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

L27 ANSWER 25 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **188530-11-2** REGISTRY

CN L-Leucine, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl- (9CI)  
(CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C45 H70 N12 O20 S2


SR CA


LC STN Files: CA, CAPLUS, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A





REFERENCE 1: 126:248257

L27 ANSWER 26 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 188530-10-1 REGISTRY

L-Tyrosine, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-prolyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C61 H88 N14 O24 S2


SR CA

LC STN Files: CA, CAPLUS, USPATFULL


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

L27 ANSWER 27 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **188530-09-8** REGISTRY

CN L-Tyrosine, N-acetyl-L-tyrosyl-L-glutamyl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-prolyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C89 H121 N19 O32 S2

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

L27 ANSWER 28 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 186378-41-6 REGISTRY

CN L-Tyrosine, L-isoleucyl-L-seryl-L-valyl-L-leucyl-L-tyrosyl-L-phenylalanyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-seryl-L-seryl-L-asparaginyl-L-valyl-L-isoleucyl-L-leucyl-L-lysyl-L-lysyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN OP-1 (human finger 2 domain large peptide-contg. fragment)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C94 H146 N20 O28

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B





—Bu-i



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:153178

L27 ANSWER 29 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **182171-30-8** REGISTRY

CN L-Leucine, N-acetyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Leucine, N-[N-[N-[N-[N-[N-[N-[N-(N-acetyl-L-.alpha.-aspartyl)-L-.alpha.-glutamyl]-L-methionyl]-L-.alpha.-glutamyl]-L-.alpha.-glutamyl]-L-cysteinyl]-L-alanyl]-L-seryl]-L-histidyl]-

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C47 H72 N12 O21 S2


SR CA

LC STN Files: CA, CAPLUS, USPATFULL


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



4 REFERENCES IN FILE CA (1962 TO DATE)  
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 134:159298

REFERENCE 2: 131:29264

REFERENCE 3: 126:248257

REFERENCE 4: 125:241572

L27 ANSWER 30 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **182171-23-9** REGISTRY

CN L-Leucine, N-acetyl-L-tyrosyl-L-glutamyl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl- (9CI)  
(CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C75 H105 N17 O29 S2

SR CA


LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



2 REFERENCES IN FILE CA (1962 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

REFERENCE 2: 125:241572

L27 ANSWER 31 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **182171-22-8** REGISTRY

CN L-Proline, N-acetyl-L-tyrosyl-L-glutamyl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl-L-leucyl- (9CI) (CA INDEX NAME)


FS PROTEIN SEQUENCE; STEREOSEARCH

MF C80 H112 N18 O30 S2


SR CA

LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C



REFERENCE 2: 125:241572

L27 ANSWER 32 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 182171-21-7 REGISTRY

CN Glycine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tyrosyl-L-glutaminyl-L-  
 .alpha.-glutamyl-L-phenylalanyl-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-  
 methionyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-cysteinyl-L-alanyl-L-  
 seryl-L-histidyl-L-leucyl-L-prolyl-L-tyrosyl-L-isoleucyl-L-.alpha.-  
 glutamyl-L-glutaminyl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

MF C120 H158 N24 O40 S2


SR CA

LC STN Files: CA, CAPLUS, USPATFULL


\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





2 REFERENCES IN FILE CA (1962 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 126:248257

REFERENCE 2: 125:241572

L27 ANSWER 33 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **178274-48-1** REGISTRY

CN L-Valine, L-valylglycyl-L-tyrosyl-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-glutamyl-L-.alpha.-glutamyl-L-seryl-L-valyl-L-lysyl-L-seryl-L-lysyl-(9CI) (CA INDEX NAME)

OTHER NAMES:

CN 17: PN: WO0214870 SEQID: 20 unclaimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C62 H100 N16 O24

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


Absolute stereochemistry.

PAGE 1-A



HO

PAGE 1-B



5 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

5 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 136:198928

REFERENCE 2: 132:121462

REFERENCE 3: 130:37290

REFERENCE 4: 127:107902

REFERENCE 5: 125:49310

L27 ANSWER 34 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 170098-67-6 REGISTRY

CN L-Methionine, L-glutaminyl-L-.alpha.-glutamyl-L-phenylalanyl-L-.alpha.-  
aspartyl-L-.alpha.-glutamyl-L-methionyl-L-.alpha.-glutamyl-L-.alpha.-  
glutamyl-L-cysteinyl-L-alanyl-L-seryl-L-histidyl-L-leucyl-L-prolyl-L-  
tyrosyl-L-isoleucyl-L-.alpha.-glutamyl-L-glutaminylglycyl- (9CI) (CA  
INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C101 H148 N24 O37 S3

SR CA

LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.

PAGE 1-A







PAGE 1-B



PAGE 1-C



PAGE 2-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 124:30420

L27 ANSWER 35 OF 37 REGISTRY COPYRIGHT 2002 ACS


RN **168691-24-5** REGISTRY

CN L-Glutamine, glycyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-aspartyl-L-glutamyl-L-isoleucyl-L-asparaginyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-lysyl-L-arginyl-L-histidyl-L-seryl- (9CI) (CA INDEX NAME)


FS PROTEIN SEQUENCE; STEREOSEARCH  
 MF C65 H103 N23 O27  
 SR CA  
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 123:246823

L27 ANSWER 36 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN **168691-23-4** REGISTRY

CN L-Glutamine, L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-L-.alpha.-aspartyl-L-glutamyl-L-methionyl-L-asparaginyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-lysyl-L-arginyl-L-histidyl-L-seryl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C66 H103 N23 O29 S

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 123:246823

L27 ANSWER 37 OF 37 REGISTRY COPYRIGHT 2002 ACS

RN 168552-66-7 REGISTRY

CN L-Serine, L-lysyl-L-seryl-L-.alpha.-aspartyl-L-asparaginyl-L-threonyl-L-lysyl-L-seryl-L-.alpha.-glutamyl-L-methionyl-L-lysyl-L-histidyl- (9CI)  
(CA INDEX NAME)

OTHER CA INDEX NAMES:

CN L-Serine, N-[N-[N2-[N-[N-[N-[N2-[N-[N2-[N-(N-L-lysyl-L-seryl)-L-.alpha.-aspartyl]-L-asparaginyl]-L-threonyl]-L-lysyl]-L-seryl]-L-.alpha.-glutamyl]-L-methionyl]-L-lysyl]-L-histidyl]-

OTHER NAMES:


CN 45: PN: US6060296 SEQID: 53 unclaimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH


MF C55 H94 N18 O22 S  
 SR CA  
 LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1962 TO DATE)  
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 132:331338

REFERENCE 2: 123:221796